Search. Learn. Save

Platform for Pharmaceutical Products for Healthcare Professionals
Search By
☰ Generic Formulas

Generic Formulas X

Aliskiren

Aliskiren: The First-in-Class Direct Renin Inhibitor in Hypertension Management

Introduction

Hypertension, or high blood pressure, remains one of the leading causes of cardiovascular morbidity and mortality worldwide. Despite numerous antihypertensive drugs available, many patients remain uncontrolled, often due to inadequate suppression of the Renin-Angiotensin-Aldosterone System (RAAS). Enter Aliskiren, a first-in-class direct renin inhibitor, developed to tackle the issue at the very start of the RAAS cascade.

Understanding the Renin-Angiotensin-Aldosterone System (RAAS)

???? The Role of RAAS in Blood Pressure Regulation

The RAAS plays a central role in maintaining blood pressure and fluid balance. It involves a complex hormonal cascade that includes:

  1. Renin – secreted by the kidneys in response to low blood pressure or sodium levels.

  2. Angiotensinogen – converted by renin into angiotensin I.

  3. Angiotensin I – converted into angiotensin II by angiotensin-converting enzyme (ACE).

  4. Angiotensin II – a potent vasoconstrictor and stimulator of aldosterone, which retains sodium and water.

Most antihypertensives (ACE inhibitors, ARBs) block downstream effects of RAAS. However, Aliskiren targets the cascade at its origin—renin—thereby offering a unique therapeutic advantage.

What is Aliskiren?

Aliskiren hemifumarate is an oral, non-peptide direct renin inhibitor (DRI) used to treat primary hypertension. It was approved by the FDA in 2007 under the brand name Tekturna (also known as Rasilez in some countries).

Unlike ACE inhibitors and ARBs, which block later steps in the RAAS, Aliskiren binds directly to renin, preventing it from converting angiotensinogen into angiotensin I, effectively stopping the cascade at the first step.

Mechanism of Action

Aliskiren works by inhibiting the enzymatic activity of renin, the rate-limiting step in the RAAS. Here's how it affects the system:

  • Blocks formation of angiotensin I and II

  • Reduces vasoconstriction

  • Decreases aldosterone secretion

  • Leads to vasodilation and natriuresis

  • Results in lower blood pressure

This direct inhibition reduces plasma renin activity (PRA), which sets it apart from ACE inhibitors and ARBs that paradoxically increase PRA due to negative feedback.

Pharmacokinetics of Aliskiren

Parameter Details
Bioavailability Low (~2.5%)
Time to peak 1–3 hours
Half-life ~24 hours
Metabolism Liver (CYP3A4 pathway)
Excretion Mostly unchanged in feces (~90%)

Note: Aliskiren should be taken consistently with regard to meals. High-fat meals can reduce its absorption.

Indications and Uses

✅ Primary Hypertension (Essential Hypertension)

  • Approved for monotherapy or in combination with other antihypertensives.

  • Especially beneficial in younger patients with high PRA levels.

???? Investigational / Off-Label Uses

  • Chronic kidney disease (CKD) (initial promise, now limited use)

  • Heart failure

  • Proteinuria reduction

  • Resistant hypertension

However, long-term benefits in CKD and heart failure have been questioned due to conflicting outcomes in large trials.

Aliskiren vs Other RAAS Inhibitors

Feature Aliskiren ACE Inhibitors ARBs
Target site Renin (early) ACE Angiotensin II receptor
PRA suppression Yes (direct) No (PRA increases) No (PRA increases)
Cough Rare Common (bradykinin) Rare
Angioedema risk Lower Higher Lower
Combination risks ↑ with ACE/ARB - -

Clinical Trials and Efficacy

???? ALLAY Trial

  • Compared Aliskiren + Losartan vs Losartan alone in patients with left ventricular hypertrophy.

  • Showed similar BP control but no superior cardiac remodeling.

???? ALTITUDE Trial

  • Evaluated Aliskiren + ACE/ARB in patients with diabetes and CKD.

  • Terminated early due to increased adverse events (stroke, hyperkalemia, renal dysfunction).

???? AVOID Trial

  • Studied Aliskiren + Losartan in diabetic nephropathy.

  • Demonstrated reduced proteinuria but did not translate into better renal outcomes.

⚠️ Key Point:

While Aliskiren is effective in lowering blood pressure, its use in combination with ACE inhibitors or ARBs is not recommended, especially in patients with diabetes or renal impairment.

Dosing Guidelines

Form Strengths Frequency
Oral tablets 150 mg, 300 mg Once daily

  • Initial dose: 150 mg daily

  • May increase to 300 mg daily if needed

  • Adjust dose based on response and tolerability

Side Effects and Safety Profile

✅ Common Side Effects:

  • Diarrhea (dose-related)

  • Dizziness

  • Headache

  • Cough (rare compared to ACEIs)

❗ Serious Adverse Effects:

  • Hyperkalemia

  • Angioedema (rare but serious)

  • Renal impairment

  • Hypotension, especially in volume-depleted patients

⚠️ Black Box Warning:

  • Do not use in pregnancy – can cause fetal toxicity and death.

  • Discontinue immediately if pregnancy is detected.

Drug Interactions

Drug/Class Effect with Aliskiren
Potassium-sparing diuretics ↑ Risk of hyperkalemia
NSAIDs ↑ Risk of renal dysfunction
ACE inhibitors / ARBs Contraindicated (↑ adverse effects)
Cyclosporine / Itraconazole ↑ Aliskiren levels (avoid combo)
Furosemide ↓ Furosemide levels (monitor)

Contraindications

  • Pregnancy

  • Concomitant use with ACE inhibitors or ARBs in diabetics

  • Severe renal impairment (eGFR <30 ml/min)

  • History of angioedema with RAAS blockers

Special Populations

????‍???? Pregnancy and Lactation:

  • Category D – contraindicated

  • May cause fetal hypotension, renal failure, or skull hypoplasia

???? Elderly:

  • Use with caution; monitor renal function and potassium

???? Pediatric Use:

  • Safety and efficacy not well established

Patient Counseling Points

  • Take Aliskiren at the same time each day.

  • Avoid potassium supplements or high-potassium foods unless advised.

  • Report symptoms like swelling of lips/tongue or difficulty breathing immediately.

  • Avoid during pregnancy and inform your doctor if planning to conceive.

  • Do not take with ACE inhibitors or ARBs, especially if diabetic.

Pros and Cons of Aliskiren

✅ Pros:

  • Targets RAAS at the origin (renin)

  • Once-daily dosing

  • Minimal cough

  • Effective BP reduction

❌ Cons:

  • Poor bioavailability

  • GI side effects

  • Hyperkalemia and renal risks

  • Not suitable in combination with other RAAS blockers

  • Not proven superior in long-term outcomes

Current Status and Market Outlook

While Aliskiren was once hailed as a breakthrough, its clinical use has declined after the ALTITUDE trial revealed risks in diabetic patients. It is now used mainly as monotherapy or second-line in non-diabetic, hypertensive patients intolerant to ACE inhibitors or ARBs.

Future Directions

???? Areas of Ongoing Research:

  • Aliskiren in resistant hypertension

  • Combination therapy with calcium channel blockers

  • Pharmacogenomics to identify responders

  • Nanoformulations to improve bioavailability

While enthusiasm has waned, Aliskiren may yet find niche roles in precision medicine strategies or controlled clinical settings.

Conclusion

Aliskiren represents a novel mechanism of blood pressure control by directly inhibiting renin. While it shows promise in certain patients, its routine use is limited due to safety concerns, especially when combined with other RAAS blockers. For select individuals, particularly those who are intolerant to ACE inhibitors or ARBs, Aliskiren offers a viable alternative with once-daily convenience and good efficacy.

As hypertension treatment becomes increasingly personalized, Aliskiren may play a role in future regimens—especially as pharmacogenomics and advanced drug delivery systems evolve.

???? References

  1. Parving HH, et al. "Cardiorenal end points in a trial of Aliskiren for type 2 diabetes." NEJM, 2012.

  2. Oparil S, et al. "The efficacy and safety of Aliskiren: Review of clinical trials." J Clin Hypertens, 2010.

  3. FDA Prescribing Information: Tekturna (Aliskiren).

  4. European Society of Cardiology Guidelines – Hypertension Management.